从物理学出发探讨癌症治疗新途径:反铂与顺铂联合应用的研究

基本信息
批准号:11674381
项目类别:面上项目
资助金额:67.00
负责人:刘玉如
学科分类:
依托单位:中国科学院物理研究所
批准年份:2016
结题年份:2020
起止时间:2017-01-01 - 2020-12-31
项目状态: 已结题
项目参与者:谢平,李波,郭思考,袁静雯
关键词:
反铂与顺铂癌症治疗医学物理新方法DNA损伤修复抗药性
结项摘要

Cancer is a leading cause of population death in China and worldwide since 2012. Genome instability and defective DNA repair are crucial signatures of cancerous tissue. Cisplatin is the “golden standard” among chemotherapy drugs in clinic. Cisplatin cures testicular cancers successfully. However, due to emerging drug resistance, other types of cancer cannot be cured by cisplatin so far. We previously discovered that cisplatin and transplatin successively linked to DNA to form complex DNA lesions which were reluctant for tumour cells to repair, by single molecular methods to reveal the dynamic process of platinum drugs interacting with DNA molecules. Cisplatin and transplatin co-treatment increased significantly the anti-tumour effect but leaved normal cells largely intact. The co-treatment of cisplatin and transplatin displays similar function profiles as cisplatin curing testicular cancer. Based on these results, we plan to investigate thoroughly the possibility and feasibility of cisplatin and transplatin coordination in animals to cure growing tumours other than testicular tumour and the safety of this method to normal tissues. The molecular mechanisms that tumour cells were killed and normal cells survived safely, as well as the mechanism of lack of drug resistance by co-treatment to enhance cisplatin clinical efficacy, will also be studied in details by combining single molecular methods, cellular biochemistry and medical animal experimental methods. The present study aims to develop a new method and strategy to cancer therapy, which would provide new insights into intervention of genome instability of cancer and functions of DNA repair systems in killing tumour cells. The single molecular, cellular and animal pre-clinical findings from this program would provide new clues for both basic research and clinical applications in cancer chemotherapy.

癌症是目前造成我国和世界人类死亡的首要因素。基因组不稳定性和DNA损伤修复能力下降是癌症发生的重要原因。顺铂是临床上使用最广泛的化疗药物,能成功治愈睾丸癌;但是由于抗药性产生,尚不能治愈其他类型癌症。我们先前通过DNA与铂类药物的单分子动态作用规律研究,发现顺铂和反铂共同作用有效形成DNA复杂铰链,明显增强顺铂的抗癌效果,超越癌细胞修复能力,并且对机体正常细胞没有明显毒性作用。这些现象与“顺铂治愈睾丸癌”机理相似。在此基础上,本项目致力于综合运用单分子、细胞生化和医学实验动物学等研究方法,全面详细研究顺铂反铂联合应用在动物机体内的安全性和杀灭体内肿瘤的有效性,以及对癌细胞杀伤和克服顺铂耐药性的分子机理和正常细胞耐受的修复代谢机理。本研究探讨癌症治疗新方法和策略,对理解癌症基因组不稳定性的可干预性和DNA损伤修复功能在癌症治疗过程中的作用机制等,具有基础研究和临床应用研究的重要参考意义。

项目摘要

项目成果
{{index+1}}

{{i.achievement_title}}

{{i.achievement_title}}

DOI:{{i.doi}}
发表时间:{{i.publish_year}}

暂无此项成果

数据更新时间:2023-05-31

其他相关文献

1

硬件木马:关键问题研究进展及新动向

硬件木马:关键问题研究进展及新动向

DOI:
发表时间:2018
2

针灸治疗胃食管反流病的研究进展

针灸治疗胃食管反流病的研究进展

DOI:
发表时间:2022
3

坚果破壳取仁与包装生产线控制系统设计

坚果破壳取仁与包装生产线控制系统设计

DOI:10.19554/j.cnki.1001-3563.2018.21.004
发表时间:2018
4

视网膜母细胞瘤的治疗研究进展

视网膜母细胞瘤的治疗研究进展

DOI:
发表时间:2018
5

原发性干燥综合征的靶向治疗药物研究进展

原发性干燥综合征的靶向治疗药物研究进展

DOI:10.13376/j.cbls/2021137
发表时间:2021

刘玉如的其他基金

相似国自然基金

1

顺铂,羰铂及宁辛铂基因损伤作用比较

批准号:38870745
批准年份:1988
负责人:王龙贵
学科分类:H3505
资助金额:3.00
项目类别:面上项目
2

高存量纳米顺铂核-铁蛋白控释顺铂机理的研究

批准号:30870515
批准年份:2008
负责人:黄河清
学科分类:C0505
资助金额:30.00
项目类别:面上项目
3

载顺铂磁性纳米药物制备及其联合放疗靶向治疗鼻咽癌的实验研究

批准号:30672297
批准年份:2006
负责人:谢民强
学科分类:H1814
资助金额:28.00
项目类别:面上项目
4

从DC-Treg轴探讨microRNA在氧化苦参碱逆转肺癌顺铂耐药中的作用

批准号:81472760
批准年份:2014
负责人:刘慧
学科分类:H1821
资助金额:60.00
项目类别:面上项目